REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights News provided by Share this article ROCKVILLE, Md., May 5, 2021 /PRNewswire/ -- Enrollment ongoing in ATMOSPHERE™, the first of two planned pivotal trials for the subretinal delivery of RGX-314 for the treatment of wet AMD Continued progress and expansion of Phase II AAVIATE ® trial of RGX-314 utilizing in-office suprachoroidal delivery for the treatment of wet AMD Began dosing in Phase I/II trial of RGX-121, a one-time gene therapy for MPS II, in pediatric patients over 5 years old Completed dosing in Cohort 1 of ongoing trial of RGX-111, a one-time gene therapy for MPS I